Pharmacotherapy for social anxiety disorder: an update.
Since the emergence of social phobia into the diagnostic nomenclature, we have seen an exponential expansion in our knowledge regarding effective treatment of this disorder. The literature clearly supports the use of SSRIs and the SNRI venlafaxine ER as first line pharmacological agents in the treatment of GSAD. In this article, treatment studies of pharmacotherapy of social phobia are summarized. Additional issues such as comparative efficacy, treatment resistance and relapse-prevention are reviewed.
Van Ameringen
Michael
M
Department of Psychiatry and Behavioural Neurosciences, McMaster University Medical Centre, Hamilton Health Sciences, Hamilton, Ontario, Canada. vanamer@mcmaster.ca
Mancini
Catherine
C
Patterson
Beth
B
Simpson
William
W
D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects / Q000627:therapeutic use; D003511:Cyclohexanols / Q000009:adverse effects / Q000627:therapeutic use; D004351:Drug Resistance; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D010698:Phobic Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D011619:Psychotropic Drugs / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D055502:Secondary Prevention; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D000069470:Venlafaxine Hydrochloride
D000927:Anticonvulsants; D018687:Antidepressive Agents, Second-Generation; D014150:Antipsychotic Agents; D001569:Benzodiazepines; D003511:Cyclohexanols; D008996:Monoamine Oxidase Inhibitors; D011619:Psychotropic Drugs; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride